KR930005633A - 성장인자 및 고분자 전해질을 함유하는 조합체 - Google Patents

성장인자 및 고분자 전해질을 함유하는 조합체 Download PDF

Info

Publication number
KR930005633A
KR930005633A KR1019920017373A KR920017373A KR930005633A KR 930005633 A KR930005633 A KR 930005633A KR 1019920017373 A KR1019920017373 A KR 1019920017373A KR 920017373 A KR920017373 A KR 920017373A KR 930005633 A KR930005633 A KR 930005633A
Authority
KR
South Korea
Prior art keywords
combination
polymer electrolyte
growth factor
peptide
fgf
Prior art date
Application number
KR1019920017373A
Other languages
English (en)
Inventor
니스 베르트홀트
Original Assignee
호이만, 쉬틀러
메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프통
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 호이만, 쉬틀러, 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프통 filed Critical 호이만, 쉬틀러
Publication of KR930005633A publication Critical patent/KR930005633A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/13—Burn treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 적어도 하나의 섬유 아세포 성장인자(FGF)의 생물학적 작용을 갖는 폴리펩티드와 적어도 하나의 양이온 고분자 전해질로 구성되어, FGF 작용의 투여개선을 이룩한 활성물질 조합체에 관한 것이다.

Description

성장인자 및 고분자 전해질을 함유하는 조합체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 적어도 하나의 FGF 작용을 갖는 펩티드와, 그위에, 적어도 하나의 양이온 고분자 전해질을 함유하는 조합체.
  2. 제1항 기재의 조합체를 제조하는 방법으로서, 적어도 하나의 FGF 작용을 갖는 펩티드의 수용액과 적어도 하나의 양이온 고분자 전해질을 함유하는 수용액을 혼합하는 것을 특징으로 하는 조합체의 제조방법.
  3. 제1항 기재의 조합체를, 적어도 하나의 고체, 액체 또는 반고체 운반체 또는 보조물질을 사용하여 적당한 투여형태로 전환시키는 것을 특징으로 하는 의약 조성물의 제조방법.
  4. 제1항 기재의 조합체를 적어도 하나 함유하는 것을 특징으로 하는 의약조성물.
  5. 질병을 제어하기 위한 제1항 기재의 조합체.
  6. 제1항 기재의 조합체를 의약품 제조목적으로 사용하는 용도.
  7. 제1항 기재의 조합체를 질병제어목적으로 사용하는 용도.
  8. 제7항에 있어서, 먼저 양이온 고분자전해질을 함유하는 성분이, 다음에 FGF작용을 갖는 펩티드를 함유하는 또 하나의 성분이 작용하도록 하는 것을 특징으로 하는 조합체의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920017373A 1991-09-26 1992-09-24 성장인자 및 고분자 전해질을 함유하는 조합체 KR930005633A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4132005A DE4132005A1 (de) 1991-09-26 1991-09-26 Kombination enthaltend wachstumsfaktoren und polyelektrolyte
DEP4132005.0 1991-09-26

Publications (1)

Publication Number Publication Date
KR930005633A true KR930005633A (ko) 1993-04-20

Family

ID=6441511

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920017373A KR930005633A (ko) 1991-09-26 1992-09-24 성장인자 및 고분자 전해질을 함유하는 조합체

Country Status (16)

Country Link
US (2) US5885960A (ko)
EP (1) EP0534310A1 (ko)
JP (1) JPH05213766A (ko)
KR (1) KR930005633A (ko)
AU (1) AU2525092A (ko)
CA (1) CA2079042A1 (ko)
CZ (1) CZ281452B6 (ko)
DE (1) DE4132005A1 (ko)
HU (1) HUT64479A (ko)
MX (1) MX9205438A (ko)
NO (1) NO923746L (ko)
PL (1) PL296034A2 (ko)
RU (1) RU2080872C1 (ko)
SK (1) SK265692A3 (ko)
TW (1) TW273512B (ko)
ZA (1) ZA927398B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7023129B1 (en) 1999-10-22 2006-04-04 Matsushita Electric Industrial Co., Ltd. Cathode-ray tube and image display comprising the same

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
US6525018B1 (en) 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
DE10022656B4 (de) * 2000-04-28 2006-07-06 Infineon Technologies Ag Verfahren zum Entfernen von Strukturen
US7538082B2 (en) 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
TW527722B (en) * 2002-03-20 2003-04-11 Macronix Int Co Ltd Non-volatile memory device and fabrication method thereof
ZA200505306B (en) * 2002-12-31 2006-09-27 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers
EP1581251B1 (en) * 2002-12-31 2016-03-16 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
CA2634053A1 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US9174839B2 (en) * 2008-01-30 2015-11-03 Imbed Biosciences, Inc. Methods and compositions for wound healing
WO2009097508A2 (en) * 2008-01-30 2009-08-06 Mcanulty, Jonathan Methods and compositions for wound healing
BRPI0801422B8 (pt) 2008-03-26 2021-05-25 Fund Sao Francisco Xavier composição e método para inibição da severidade das aderências pós-cirúrgicas
JP5767314B2 (ja) 2010-04-16 2015-08-19 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｇｆを用いて代謝障害を処置するための方法
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
CA3002400A1 (en) 2015-10-30 2017-05-04 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs
CN109843343A (zh) 2016-07-29 2019-06-04 因贝德生物科学公司 用于伤口愈合的方法和组合物
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
RU2734819C1 (ru) * 2019-12-12 2020-10-23 Общество с ограниченной ответственностью "ИНТЭКОС" (ООО "ИНТЭКОС") Композиция для лечения ран и ожогов (варианты)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783412A (en) * 1983-07-05 1988-11-08 Chiron Corporation Hybrid DNA synthesis of epidermal growth factor
US4956455A (en) * 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
JPS61253065A (ja) * 1985-05-02 1986-11-10 片倉チツカリン株式会社 キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法
DE3689845T3 (de) * 1985-09-12 2001-11-15 Scios Inc., Sunnyvale Rekombinanter fibroblast-wachstumsfaktor.
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7023129B1 (en) 1999-10-22 2006-04-04 Matsushita Electric Industrial Co., Ltd. Cathode-ray tube and image display comprising the same

Also Published As

Publication number Publication date
DE4132005A1 (de) 1993-04-01
NO923746L (no) 1993-03-29
US5885960A (en) 1999-03-23
PL296034A2 (en) 1993-07-12
HU9203079D0 (en) 1992-12-28
EP0534310A1 (de) 1993-03-31
SK265692A3 (en) 1994-06-08
CZ265692A3 (en) 1993-04-14
ZA927398B (en) 1993-04-02
TW273512B (ko) 1996-04-01
RU2080872C1 (ru) 1997-06-10
AU2525092A (en) 1993-04-01
CZ281452B6 (cs) 1996-10-16
NO923746D0 (no) 1992-09-25
US6147053A (en) 2000-11-14
MX9205438A (es) 1993-03-01
HUT64479A (en) 1994-01-28
JPH05213766A (ja) 1993-08-24
CA2079042A1 (en) 1993-03-27

Similar Documents

Publication Publication Date Title
KR930005633A (ko) 성장인자 및 고분자 전해질을 함유하는 조합체
NO995367L (no) Aktivert Vitamin D3-emulsjonstype losjoner
DE68903846D1 (de) Neue galenische form von fenofibrat.
KR910001044A (ko) 안정화된 fgf 조성물 및 그의제조
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
DE69233188D1 (de) Hormonanaloge mit mehreren ctp-erweiterungen
ATE74519T1 (de) Waessrige loesung von fettloeslichen wirkstoffen.
DE69230670D1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
CO5150160A1 (es) Formulacion antisudoral para aplicador poroso
DE69001991D1 (de) Fluessige arzneimittel zur nasalen anwendung, die ein polypeptid als wirksubstanz enthalten.
FI923347A0 (fi) Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
CA2189947A1 (en) Use of von willebrand factor and pharmaceutical formulation
KR890015742A (ko) 이병치료용 국소 제제
ATE54824T1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
ATE64526T1 (de) Zubereitung von pregnanolol in einer stabilen oel- in-wasser-emulsion.
DE3854290D1 (de) Stabilisierung von therapeutisch wirksamen Proteinen in pharmazeutischen Zubereitungen.
KR930019224A (ko) 유산 위험 치료제
KR960701657A (ko) 피부 상처 치료용 인자 XIII (Factor XIII for treatment of skin wounds)
KR880000094A (ko) 위염치료제
ATE48616T1 (de) Analoge von hypokalzemischen polypeptiden, welche den kalziumgehalt des koerpers schonen, deren herstellung, deren verwendung als arznei und diese enthaltende zusammensetzungen.
KR920021154A (ko) 만성 정맥혈울성 궤양의 치료와 상피재형성에 국부적으로 사용되는 제약학적 성분물
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR910007540A (ko) 혈구 감소 장해의 예방ㆍ치료제
KR900012622A (ko) 피부질환치료 조성물
KR940021082A (ko) 생체조직보전형성조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application